AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company developing novel small molecule therapeutics derived from its boron chemistry platform, today announced the initiation ...
(RTTNews) - AN2 Therapeutics Inc. (ANTX) announced that the U.S. FDA has cleared its investigator-initiated trial evaluating Epetraborole in 90 patients with Mycobacterium abscessus lung disease, ...
A team of scientists has developed a novel antibiotic named COE-PNH2 that is capable of combating hard-to-treat mycobacterial lung infections. Such infections, which are notorious for resisting ...
MENLO PARK, Calif.--(BUSINESS WIRE)-- AN2 Therapeutics, Inc. (ANTX), a biopharmaceutical company advancing novel small molecule therapeutics derived from its boron chemistry platform, today announced ...
New treatment options for treating Mycobaterium abscessus infections are needed. Previous findings had identified the leucyl-tRNA synthetase inhibitor MRX-6038 to have significant activity against M.
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company developing novel small molecule therapeutics derived from its boron chemistry platform, today announced the initiation ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results